Posts by John Bucksath, CEO
John Bucksath, CEO and Board Member at KCAS Bioanalytical and Biomarker Services since 2016, steers the organization's strategy. Also, he actively contributes to the boards of the Missouri Biotechnology Association and BioKansas, serves on the University of Missouri’s Research and Development Advisory Board, and participates in the Mizzou Venture Mentoring Program for life sciences startups.
Blogs
Global drug development now operates across borders by default. Pharmaceutical and biotech R&D routinely spans multiple countries, driven by competitive timelines, access to patients, and the need for specialized expertise. Governments have responded by actively courting development programs through incentives, talent investment, and streamlined infrastructure. Australia remains a strong example,…
Blogs
Drawing on the insights of our leadership team, we’ve compiled a global perspective on the state of the bioanalytical industry in 2024. Through thoughtful discussions with our CEO, John Bucksath, and key team members Amy Mize, Mouhssin Oufir, and Brian Wile, KCAS Bio delivers a roadmap…
Blogs
With 2022 firmly planted in our rearview mirror, and the planning for the new year essentially complete, we all look forward to a new year with cautious optimism as we wait to…
Blogs
Thank you for your interest in learning about KCAS. Founded in 1979, KCAS has become one of the fastest growing Bioanalytical and Biomarker facilities within our industry. KCAS is a progressive growing contract research…
Blogs
The paradigm of drug development outsourcing is in a period of rapid transition coupled with a growing market in a competitive space. Today’s service providers are hardly recognizable from a decade ago and if the continued evolution in the market is any indicator, it is safe to say the next…